

# REAL-WORLD EFFECTIVENESS AND SAFETY OF RIMEGEPANT IN MIGRAINE PROPHYLAXIS

C. MOYA MANGAS<sup>1</sup>, L. AMARO ALVAREZ<sup>1</sup>, J. CORDERO RAMOS<sup>1</sup>, J.A. MARCOS RODRIGUEZ<sup>1</sup>  
1. HOSPITAL UNIVERSITARIO VIRGEN MACARENA, HOSPITAL PHARMACY, SEVILLA, SPAIN

## Background and importance

Rimegepant is a calcitonin gene-related peptide receptor antagonist indicated for migraine prophylaxis in adults with at least four migraine days per month.


## Aim and objectives

Evaluate the real-world effectiveness and safety of rimegepant.

## Results

46 patients. 80.4% female, 44.0 ± 13.8 years.  
Baseline: HIT-6 score: 62.0 ± 3.7; VAS: 8 (7-9)

## Material and methods



Tertiary-care hospital Jan 2024 - Jul 2025.



Variables: sex, age, dose, duration, migraine attacks before/after treatment, previous prophylactic drugs, adverse events.



Headache Impact Test (HIT-6), the Visual Analogue Scale (VAS), and the Patient Global Impression of Change (PGIC).


R 4.1.1. and Wilcoxon test.



Prior prophylactic drugs: 5.0 (4-7)  
Duration: 8.0 (4.6-13.6) months  
Dose: 75 mg/48h.  
Adherence: 89.1%

### Migraine


\*(High-frequency episodic migraine)



■ Chronic ■ HFEM\*

### Adverse events

34.8% of patients



■ Asthenia ■ Dyspepsia ■ Nausea

Baseline migraine attacks: 10 (8-11) → 4 (3-8) (p<0.001)

Baseline PGIC: 4 (4-6) → 3 (2-4) (p<0.01)

Discontinuation: 23.9% (N=10) → 5 due to adverse events

### Prior prophylactic drugs

3 biologic agents

Zonisamide

Topiramate

Flunarizine

Amitriptyline

0,00% 20,00% 40,00% 60,00% 80,00% 100,00%

## Conclusion and relevance

Effective and safe.  
Reduction in migraine frequency and an improvement in patient-reported outcomes.  
Adverse events mild and easily.  
Further studies are needed.

## Contact data



Celia Moya Mangas  
[celia.moya.sspa@juntadeandalucia.es](mailto:celia.moya.sspa@juntadeandalucia.es)  
Hospital Universitario Virgen Macarena.  
Av. Dr. Fedriani, 3. Sevilla, 41009.

4CPS-123

